CTXR — Citius Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1506251 ·
Last close
$0.52
Market Cap
$14.24M
52W High
$1.54
52W Low
$0.37
ADV30
263,707
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 1,493,788 1,001,945 -10,011,762 -8,862,843 142,255,198 17,007,523 66,346,742
Mar 2026 1,667,298 1,338,420 -30,474,474 -21,231,140 132,540,579 4,590,174 63,456,026
Dec 2025 3,944,111 3,154,903 -8,445,770 -8,220,785 140,391,730 7,721,393 46,923,760
Sep 2025 0 — -8,437,309 -7,959,288 130,938,025 4,252,290 53,410,425

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-34,867,203
Investing CF
$-7,000,000
Financing CF
$58,535,600
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.47
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-277,118,897
Inventory
$22,625,945
Receivables
$686,235
ST Investments
—
EBIT TTM
$-57,460,797
Pretax Income TTM
$-57,976,618
Interest Exp TTM
$515,821
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$7,105,197
EBITDA
$-53,851,096
Free Cash Flow
$-36,803,784
Enterprise Value
$15,414,862
Total Cash
$17,007,524
Total Debt
$7,177,118
Shares Out
27,452,570
Trailing EPS
$-1.75
Book Value
$2.43
ROE
-81.1%
ROA
-26.6%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Sep 2025 0 -38,525,608 -37,433,911 130,938,025 53,410,425 67,550,178 -26,552,738
Sep 2024 0 -41,995,681 -39,138,839 116,651,751 42,549,921 70,077,450 -28,201,375
Sep 2023 0 -36,732,018 -32,542,912 103,611,150 12,179,662 90,831,108 -29,060,212
Sep 2022 0 -33,316,045 -33,640,646 113,999,302 10,573,057 102,825,865 -28,361,256

TTM Snapshot

Revenues TTM
$7,158,620
NetIncome TTM
$-46,274,056
OpCashFlow TTM
—
Assets (Latest)
$142,255,198
Forward EPS
$-1.44

Peers — same industry

TickerNameMarket CapLastDaily %
MCRB Seres Therapeutics, Inc. $14.37M $1.41 —
INTI Inhibitor Therapeutics, Inc. $13.98M $0.08 —
KTTA Pasithea Therapeutics Corp. $14.51M $0.43 —
MRKR Marker Therapeutics, Inc. $13.95M $0.84 —
ACTU ACTUATE THERAPEUTICS, INC. $13.84M $0.25 —

News headlines (Yahoo Finance, 1h cache)

Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
2026-11-11 13:30 · Yahoo
Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
2026-10-12 12:30 · Yahoo
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
2026-08-12 12:00 · Yahoo
Citius Pharmaceuticals Secures $5M Through Equity Offering
2026-04-24 14:48 · Yahoo
We Might See A Profit From Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Soon
2026-04-21 17:09 · Yahoo
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
2026-04-24 20:30 · Yahoo
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?
2026-05-24 11:49 · Yahoo
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
2026-04-24 12:00 · Yahoo
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
2026-10-26 17:00 · Yahoo
Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe
2026-11-04 18:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.